GT Biopharma Files S-1 Registration
Ticker: GTBP · Form: S-1 · Filed: Dec 23, 2024 · CIK: 109657
Sentiment: neutral
Topics: s-1, registration, pharmaceutical
TL;DR
GT Biopharma just filed an S-1, get ready for a potential stock event.
AI Summary
GT Biopharma, Inc. filed an S-1 registration statement with the SEC on December 23, 2024. The company, previously known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 315 Montgomery Street, 10th Floor, San Francisco, CA 94104, with a contact phone number of (415) 919-4040.
Why It Matters
This S-1 filing indicates GT Biopharma is preparing to offer securities to the public, which could lead to significant capital infusion or dilution for existing shareholders.
Risk Assessment
Risk Level: medium — As a newly registered entity for public offering, the company's future performance and market reception are uncertain.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
- 19940916 — Date of Name Change (Marks the transition from OXIS INTERNATIONAL INC.)
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
- Michael Breen (person) — Interim Chief Executive Officer
- 315 Montgomery Street, 10th Floor San Francisco, CA 94104 (location) — Principal Executive Offices
- 2834 (industry_code) — Standard Industrial Classification Code
- 333-284032 (registration_number) — SEC File Number
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on December 23, 2024.
What is GT Biopharma, Inc.'s primary business sector?
GT Biopharma, Inc. operates in the Pharmaceutical Preparations sector, indicated by the SIC code 2834.
Who is the current Interim Chief Executive Officer of GT Biopharma, Inc.?
Michael Breen is the Interim Chief Executive Officer of GT Biopharma, Inc.
What are GT Biopharma, Inc.'s principal executive offices?
The company's principal executive offices are located at 315 Montgomery Street, 10th Floor, San Francisco, CA 94104.
Filing Stats: 4,499 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2024-12-23 17:23:43
Key Financial Figures
- $0.001 — ”) of our common stock, par value $0.001 per share (“common stock”)
- $0.0001 — of common stock at an exercise price of $0.0001 per share. Each pre-funded warrant is b
- $1.75 — stock on the Nasdaq Capital Market was $1.75 per share. All share, common warrant an
- $100,000 — d expenses in an aggregate amount up to $100,000. In addition, we have agreed to issue t
Filing Documents
- forms-1.htm (S-1) — 805KB
- ex23-1.htm (EX-23.1) — 5KB
- ex107.htm (EX-FILING FEES) — 33KB
- forms-1_001.jpg (GRAPHIC) — 10KB
- forms-1_003.jpg (GRAPHIC) — 91KB
- forms-1_004.jpg (GRAPHIC) — 20KB
- forms-1_005.jpg (GRAPHIC) — 35KB
- forms-1_009.jpg (GRAPHIC) — 12KB
- forms-1_010.jpg (GRAPHIC) — 52KB
- forms-1_011.jpg (GRAPHIC) — 52KB
- forms-1_012.jpg (GRAPHIC) — 1393KB
- 0001493152-24-051873.txt ( ) — 3138KB
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 17
description of securities we are offering
description of securities we are offering 20 MATERIAL TAX CONSIDERATIONS 23 PLAN OF DISTRIBUTION 29 I ncorporation of certain information by reference 32 WHERE YOU CAN FIND MORE INFORMATION 33 LEGAL MATTERS 33 EXPERTS 33 i ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “ Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “ Incorporation of Certain Information by Reference ,” before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys genera